Description: ASLAN Pharmaceuticals Ltd is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies. Its products include Varlitinib, ASLAN002, ASLAN003, ASLAN004, ASLAN005, and Modybodies.
Home Page: aslanpharma.com
ASLN Technical Analysis
83 Clemenceau Avenue
Singapore,
239920
Singapore
Phone:
65 6222 4235
Officers
| Name | Title |
|---|---|
| Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. | Founder, CEO & Exec. Director |
| Mr. Kiran Kumar Asarpota | COO & Head of Fin. |
| Mr. Ben Goodger | Gen. Counsel |
| Mr. Stephen Doyle | Chief Bus. Officer |
| Charlie Hsu | Investor Relations Director |
| Chi-Chin Wang | IR & Corp. Devel. Director |
| Dr. Alexandre Kaoukhov M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5836 |
| Price-to-Sales TTM: | 19.0541 |
| IPO Date: | 2018-05-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 27 |